In the last trading session, 17.47 million AbCellera Biologics Inc (NASDAQ:ABCL) shares changed hands as the company’s beta touched 0.38. With the company’s per share price at $3.02 changed hands at $0.51 or 20.32% during last session, the market valuation stood at $901.43M. ABCL’s last price was a discount, traded about -21.85% off its 52-week high of $3.68. The share price had its 52-week low at $1.89, which suggests the last value was 37.42% up since then.
Analysts gave the AbCellera Biologics Inc (ABCL) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.25. If we narrow down to specifics, the data shows that 0 out of 9 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended ABCL as a Hold, 7 felt it is a Buy and 0 rated the stock as Underweight. AbCellera Biologics Inc’s EPS for the current quarter is expected to be -0.16.
AbCellera Biologics Inc (NASDAQ:ABCL) trade information
Instantly ABCL was in green as seen at the end of in last trading. With action 30.74%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 3.07%, with the 5-day performance at 30.74% in the green. However, in the 30-day time frame, AbCellera Biologics Inc (NASDAQ:ABCL) is 48.77% up.
The consensus price target for the stock as assigned by Wall Street analysts is 23.5, meaning bulls need an upside of 87.15% from its current market value. According to analyst projections, ABCL’s forecast low is 5 with 34 as the target high. To hit the forecast high, the stock’s price needs a -1025.83% plunge from its current level, while the stock would need to soar -65.56% for it to hit the projected low.
AbCellera Biologics Inc (ABCL) estimates and forecasts
Year-over-year growth is forecast to reach -9.62% down from the last financial year.
Consensus estimates given by 9 financial analysts project the company’s revenue in the current quarter to hit an average of 7.55M. 9 analysts are of the opinion that AbCellera Biologics Inc’s revenue for the current quarter will be 7.57M. The company’s revenue for the corresponding quarters a year ago was 7.32M and 6.51M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 3.04%. The estimates for the next quarter sales put growth at 16.35%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -107.74%. The 2025 estimates are for AbCellera Biologics Inc earnings to decrease by -10.77%, but the outlook for the next 5-year period is at 0.83% per year.
AbCellera Biologics Inc (NASDAQ:ABCL)’s Major holders
BAILLIE GIFFORD & CO holds the second largest percentage of outstanding shares, with 7.4472% or 21.91 million shares worth $64.86 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were SMALLCAP WORLD FUND INC and iShares Trust-iShares Biotechnology ETF. With 13.36 shares estimated at $40.35 million under it, the former controlled 4.48% of total outstanding shares. On the other hand, iShares Trust-iShares Biotechnology ETF held about 0.48% of the shares, roughly 1.42 shares worth around $4.28 million.
